There has been growing concern about ghostwriting practices in peer-reviewed biomedical journals. As a result, various proposals have been put forth to abolish or prevent the practice of ghostwriting. In this article, we review the issues underlying ghostwriting in medical research; highlight the shared responsibilities of the pharmaceutical industry and other trial sponsors, medical centers and journal editors; and propose a roadmap for an effective policy on the ethical, transparent and reliable communication of results of clinical research.
Contents
- Article
-
Requires Authentication UnlicensedToward a Pragmatic Policy on AuthorshipLicensedOctober 25, 2011
-
Requires Authentication UnlicensedSharper p-Values for Stratified Election AuditsLicensedOctober 26, 2011
-
Requires Authentication UnlicensedAssessing the Early Aberration Reporting System's Ability to Locally Detect the 2009 Influenza PandemicLicensedMay 18, 2011
-
Requires Authentication UnlicensedThe Spread of Evidence-Poor Medicine via Flawed Social-Network AnalysisLicensedMay 18, 2011
-
Requires Authentication UnlicensedUsing a Density-Variation/Compactness Measure to Evaluate Redistricting Plans for Partisan Bias and Electoral ResponsivenessLicensedMay 18, 2011
- Commentary and Ideas
-
Requires Authentication UnlicensedReproducible Research: A Range of ResponseLicensedMay 20, 2011
-
Requires Authentication UnlicensedWhat Can We Predict About Libya and the Arab Spring from Statistical Studies?LicensedJune 24, 2011
- Response or Comment
-
Requires Authentication UnlicensedComment on Alemayehu and Levenstein "Toward a Pragmatic Policy on Authorship"LicensedOctober 26, 2011
-
Requires Authentication UnlicensedDiscussion of Alemayehu and LevensteinLicensedNovember 7, 2011